[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100649566":3},{"organization":4,"armGroups":7,"interventions":18,"overallOfficials":22,"centralContacts":25,"locations":31,"responsibleParty":43,"collaborators":22,"id":45,"slug":46,"hasResults":47,"nctId":48,"briefTitle":49,"officialTitle":49,"acronym":22,"eligibilityCriteria":50,"healthyVolunteers":47,"sex":51,"minAge":52,"maxAge":53,"enrollmentInfo":54,"targetDuration":22,"studyType":57,"phases":58,"briefSummary":60,"conditions":61,"keywords":63,"overallStatus":34,"whyStopped":22,"lastUpdateSubmitDate":64,"lastUpdatePostDateStruct":65,"startDateStruct":68,"completionDateStruct":70,"leadSponsor":72,"locationsCount":73},{"fullName":5,"class":6},"Fu Jen Catholic University Hospital","OTHER",[8,13],{"label":9,"type":10,"description":9,"interventionNames":11},"GLP-1 stop for 1 week","ACTIVE_COMPARATOR",[12],"Behavioral: GLP-1 stop for 1 week",{"label":14,"type":15,"description":14,"interventionNames":16},"GLP-1 not stop for 1 week","PLACEBO_COMPARATOR",[17],"Behavioral: GLP-1 not stop for 1 week",[19,23],{"type":20,"name":14,"description":14,"armGroupLabels":21,"otherNames":22},"BEHAVIORAL",[14],null,{"type":20,"name":9,"description":9,"armGroupLabels":24,"otherNames":22},[9],[26],{"name":27,"role":28,"phone":29,"phoneExt":22,"email":30},"Kuan I Sung","CONTACT","+886928139643","ioudanny520@hotmail.com",[32],{"facility":33,"status":34,"city":35,"state":36,"zip":37,"country":36,"countryCode":38,"cosmosGeoPoint":22,"geoPoint":22,"contacts":39},"FJUH","RECRUITING","New Taipei","Taiwan","24352","TW",[40],{"name":27,"role":28,"phone":41,"phoneExt":22,"email":42},"0928139643","danny520julia@gmail.com",{"type":44,"investigatorFullName":22,"investigatorTitle":22,"investigatorAffiliation":22,"oldNameTitle":22,"oldOrganization":22},"SPONSOR","100649566","discontinuation-recommendations-for-glp-1-receptor-agonists-prior-to-colonoscopy-a-randomized-controlled-trial-in-taiwan-100649566",false,"NCT07736963","Discontinuation Recommendations for GLP-1 Receptor Agonists Prior to Colonoscopy: A Randomized Controlled Trial in Taiwan.","Inclusion Criteria:\n\n* Inclusion Criteria for non GLP-1 user:\n\n  * Individuals who are scheduled to undergo total colonoscopy for any reasons\n  * Age between 18 to 70 years.\n  * ECOG Performance status is 0 or 1.\n  * Written consent to participate in the study has been obtained.\n  * Outpatient department patient\n  * Stop at least 3 days if current using medications that promote or inhibit gastrointestinal motility.\n\nExclusion Criteria:\n\n* • Presence of severe comorbid conditions that preclude the safe performance of colonoscopy (e.g., unstable angina, recent myocardial infarction, decompensated heart failure, chronic respiratory disease, or bleeding diathesis).\n\n  * History of prior gastric, small bowel, or colorectal segmental resection (patients with isolated appendectomy are eligible).\n  * Family history of hereditary colorectal cancer syndromes.\n  * Current or prior diagnosis of inflammatory bowel disease.\n  * Known colorectal polyposis syndromes.\n  * Any other condition deemed inappropriate for study participation at the discretion of the treating physician.\n  * Body mass index (BMI) \\> 40 kg\u002Fm².\n  * Diagnosis of liver cirrhosis.\n  * Diagnosis of Parkinson's disease.\n  * Diagnosis of dementia.\n  * Use of tricyclic antidepressants or opioid medications for more than 3 months.","ALL","18 Years","90 Years",{"count":55,"type":56},240,"ESTIMATED","INTERVENTIONAL",[59],"NA","This study aims to evaluate the impact of different discontinuation intervals of GLP-1 receptor agonists prior to colonoscopy on bowel preparation quality and the need for repeat colonoscopy, in order to establish appropriate discontinuation recommendations.",[62],"GLP-1",[62],"2026-07-26",{"date":66,"type":67},"2026-07-30","ACTUAL",{"date":69,"type":67},"2026-06-01",{"date":71,"type":56},"2028-06-01",{"name":5,"class":6},1]